Tuesday, October 16, 2018 9:31:33 AM
People throw out "buy-out" all the time on the OTC and it rarely happens and even less so for companies with no revenues or assets.
Fully diluted share count is about 1.2B currently and that excludes convertible debt.
So even with an insane purchase price of $30M, you'd take $1M off the top for payoff of debt and you'd end up with .024 a share, and what would someone actually be getting for that purchase price? Companies current assets are $200k and that includes $92k in loan receivable from related party PAOG, so there is nothing to buy and Cannophen is not anything to buy either as why would a company spend a lot of money for Cannophen when they could just make it themselves fora fraction of the cost?
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM